ERBB2 and gastric cancer: Above all, our study elucidates a novel survival signaling pathway during the progression of adaptive lapatinib resistance in HGC-27 cells, and targeting NONHSAT160169.1 is expected to be a potential therapeutic strategy for overcoming lapatinib resistance in HER2-positive gastric cancer.